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Gouty	 arthritis	 is	 a	 common	 type	 of	 arthritis	 that	 affects	
approximately	2%	of	 the	adult	population.	 Interleukin-1β	 (IL-
1β)−mediated	 inflammation	that	 is	 triggered	by	monosodium	











































































for	 some	patients	with	gouty	arthritis	 referred	 to	a	 tertiary	
care	 hospital,	 particularly	 by	 general	 practitioners	 or	 other	
specialists,	 as	 these	 patients	 have	 the	 most	 severe	 disease	
and/or	major	comorbidities.	Evidence	shows	that	at	the	time	
of	diagnosis,	patients	with	gouty	arthritis	have	a	significantly	

























































































































































































































































Recent	 evidence	 suggests	 that	 interleukin-1	 (IL-1),	 a	
proinflammatory	cytokine,	plays	a	major	role	 in	mediating	












































































to	 Optimize	 ULT	 in	 a	 Patient	 with	 Difficult-to-Treat	 Gouty	
Arthritis”.





Persistent	 Gout	 Flares	 Complicated	 by	 Comorbidities	 and	
Polypharmacy:	An	Evidence-based	Approach.”
Roberto	 Scarpioni	 is	 the	 author	 of	 clinical	 cases:	 “An	
Innovative	Approach	to	Managing	a	Patient	With	Complicated	
Gouty	Arthritis	and	Chronic	Kidney	Disease”	and	“What	is	the	












eS28	 W.A. Schmidt et al. / Joint Bone Spine 82 (2015) eS17-eS29


































































[18]	 Zhang	 W,	 Doherty	 M,	 Bardin	 T,	 et	 al.	 EULAR	 evidence	






























































































acid	 crystals	 activate	 the	 NALP3	 inflammasome.	 Nature	
2006;440:237−41.	
[47]	 Fang	 L,	 Xie	 D,	 Wu	 X,	 et	 al.	 Involvement	 of	 Endoplasmic	
Reticulum	 Stress	 in	 Albuminuria	 Induced	 Inflammasome	















after	 therapy	 with	 human	 anti-interleukin-1β	 monoclonal	
antibody	 canakinumab.	 Clin	 Rheumatol	 Clin	 Rheumatol	
2015;34:1311-6.
